NASDAQ, ACAD - Acadia Pharmaceutica

We are a biopharmaceutical company focused on the discovery, development, and  commercialization of small molecule drugs for the treatment of central nervous  system disorders. We currently have six clinical programs and several additional  programs in discovery and development. In our most advanced program, we are  conducting Phase III studies with pimavanserin for the treatment of Parkinson?s  disease psychosis. We have reported positive results from a Phase II trial in  our program with pimavanserin as a co-therapy in schizophrenia. We also have  completed enrollment of a Phase IIb trial in our program with ACP-104 as a  stand-alone treatment for schizophrenia. In addition, we have completed a  proof-of-concept clinical study with pimavanserin for the treatment of sleep  maintenance insomnia in healthy older adults. We have retained worldwide  commercialization rights for our programs with pimavanserin and ACP-104.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	15.292
PEG Ratio:	N/A
EPS:	1.37
DivYield:	N/A
PtB:	4.5752
PtS:	67.33
EBITDA:	N/A
Shares:	167.36M
Market Cap:	4.119B
52wk range:	13.40 - 25.23

216.73.216.229
United States